引言：从"传统化药企业"到"技术平台型药企"的转型 过去二十余年，莱美药业一直以化学制药业务为核心，产品覆盖抗肿瘤、消化系统、抗感染等多个治疗领域，其中最具代表性的产品是纳米炭混悬注射 液（卡纳琳）。 该产品是国内首个获批上市的肿瘤淋巴示踪剂，经过多年临床应用和市场推广，在市场上保持了较高的市场占有率，目前已在甲状腺、乳腺、胃肠及妇 科肿瘤等多个外科手术场景中得到广泛使用，并逐渐成为相关手术淋巴结清扫的重要辅助工具。 莱美药业的发展逻辑正在从过去以单一创新产品为核心的经营模式，逐步转向以技术平台为基础、以多产品创新组合为支撑的结构性升级。 公司参股公 司康德赛作为聚焦"mRNA+细胞疗法"的创新型生物医药企业，凭借技术突破、临床进展、产业合作及政策适配等多重优势，在肿瘤治疗、纤维化修复等 领域构建起核心竞争力，康德赛用于治疗晚期卵巢癌的个体化肿瘤疫苗项目（CUD002）、用于治疗中晚期肝硬化的巨噬细胞项目（CUD005）临床一期 均在稳步推进过程中。 对于一家深耕化学制药多年的企业而言，这种转型既是应对行业环境变化的必然选择，也可能成为未来重新打开成长空间的重要起点。 0 2 业绩短期承压，战略转型成效初显 ...

Core Viewpoint - Guangxi Wuzhou Zhongheng Group Co., Ltd. has successfully transformed from a traditional pharmaceutical company to a technology-driven enterprise during the "14th Five-Year Plan" period, focusing on innovation and research and development in traditional Chinese medicine and chemical drugs [1][2]. Innovation in Pharmaceuticals - Zhongheng Group has made significant strides in innovative drugs, particularly with the "Sanqi Granules," which received clinical trial approval from the National Medical Products Administration, targeting chronic kidney disease [2][3]. - The market for chronic kidney disease in China is substantial, with approximately 150 million patients and a market size exceeding 32 billion yuan, indicating a significant opportunity for the company [2]. Product Development and Brand Value - The company has been actively involved in the secondary development of core products, with the "Zhonghua Die Da Wan" being recognized as one of the "China's 500 Most Valuable Brands," valued at over 10 billion yuan [3]. - Zhongheng Group is expanding into cardiovascular disease treatments, with a new innovative drug targeting chronic heart failure, addressing a market with over 12 million patients in China [3]. Research and Development Investment - From 2021 to 2024, Zhongheng Group invested nearly 687 million yuan in R&D, accounting for 6.11% of its revenue, establishing a robust research funding mechanism [5]. - The company has formed partnerships with national key laboratories and universities to enhance its research capabilities and facilitate the transition from research to industry [5]. Smart Manufacturing and Technology Integration - Zhongheng Group has integrated modern technology into its manufacturing processes, significantly improving production efficiency, with the solid preparation workshop achieving a production rate of 1,000 pills per minute [6]. - The company holds 343 valid patents and has received multiple awards for its innovations, showcasing its commitment to modernizing traditional practices [6]. Brand Expansion and Market Reach - The company has successfully modernized its product offerings, such as the "Guilinggao," which has evolved from a traditional dessert to a health food product, now available in various convenient packaging [7][8]. - Zhongheng Group's brands have entered high-end retail markets and expanded online, contributing to a combined brand value exceeding 40 billion yuan during the "14th Five-Year Plan" [9].